Abstract

BackgroundPresently, there is no effective treatment for the lethal muscle wasting disease Duchenne muscular dystrophy (DMD). Here we show that increased sphingosine-1-phoshate (S1P) through direct injection or via the administration of the small molecule 2-acetyl-4(5)-tetrahydroxybutyl imidazole (THI), an S1P lyase inhibitor, has beneficial effects in acutely injured dystrophic muscles of mdx mice.MethodsWe treated mdx mice with and without acute injury and characterized the histopathological and functional effects of increasing S1P levels. We also tested exogenous and direct administration of S1P on mdx muscles to examine the molecular pathways under which S1P promotes regeneration in dystrophic muscles.ResultsShort-term treatment with THI significantly increased muscle fiber size and extensor digitorum longus (EDL) muscle specific force in acutely injured mdx limb muscles. In addition, the accumulation of fibrosis and fat deposition, hallmarks of DMD pathology and impaired muscle regeneration, were lower in the injured muscles of THI-treated mdx mice. Furthermore, increased muscle force was observed in uninjured EDL muscles with a longer-term treatment of THI. Such regenerative effects were linked to the response of myogenic cells, since intramuscular injection of S1P increased the number of Myf5nlacz/+ positive myogenic cells and newly regenerated myofibers in injured mdx muscles. Intramuscular injection of biotinylated-S1P localized to muscle fibers, including newly regenerated fibers, which also stained positive for S1P receptor 1 (S1PR1). Importantly, plasma membrane and perinuclear localization of phosphorylated S1PR1 was observed in regenerating muscle fibers of mdx muscles. Intramuscular increases of S1P levels, S1PR1 and phosphorylated ribosomal protein S6 (P-rpS6), and elevated EDL muscle specific force, suggest S1P promoted the upregulation of anabolic pathways that mediate skeletal muscle mass and function.ConclusionsThese data show that S1P is beneficial for muscle regeneration and functional gain in dystrophic mice, and that THI, or other pharmacological agents that raise S1P levels systemically, may be developed into an effective treatment for improving muscle function and reducing the pathology of DMD.

Highlights

  • There is no effective treatment for the lethal muscle wasting disease Duchenne muscular dystrophy (DMD)

  • Alterations of S1P regulation and content following IP injection of tetrahydroxybutyl imidazole (THI) in mdx mice To determine the effect of elevating S1P levels in dystrophic animals, we studied the effects of THI in the mdx mouse model for DMD [23,24]

  • Loh et al (2012) showed that compared to wt, mdx muscles are in a state of S1P deprivation as they exhibit increased levels of the enzymes that degrade S1P (S1P lyase and S1P phosphatase 1) [8]

Read more

Summary

Introduction

There is no effective treatment for the lethal muscle wasting disease Duchenne muscular dystrophy (DMD). Duchenne muscular dystrophy (DMD) is a muscle wasting disease for which there is no cure. Sphingosine-1-phosphate (S1P) has been implicated in muscle repair, satellite cell proliferation, myoblast differentiation in vitro and in non-diseased mouse models in vivo [2,4,5,6]. These essential roles for S1P in skeletal muscle regeneration suggested that elevation of S1P may have therapeutically beneficial effects in models of disease [7]. S1P has been shown beneficial for activating satellite cells in dystrophic muscles [8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call